WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition. Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription. “While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free. The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS. |
Quake death toll surpasses 15,000 in Türkiye, SyriaChina calls for efforts to promote Colombia's national developmentLandmark loss and damage fund approved as UN climate conference closes in EgyptChina calls for intensified diplomatic efforts to end Ukraine crisisChina urges the U.S. to correct its wrongdoing against Chinese studentsJapan's discharge planChina calls for intensified diplomatic efforts to end Ukraine crisisChina approves first cargo airportFeature: Race against time to find survivors at epicenter of Türkiye's massive earthquakesUN responds to devastating ferry tragedy in Mozambique